The Patent Finder
AT

Adneuris Therapeutics, Inc.

First filing 2009
OverviewNotableFeesChangesFamiliesPatent listSources & methods

Previously recorded as Park Therapeutics, Inc. (to 2025)

19 patents currently held

1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Aug 2031. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Aug 2031
Next term end
14
Patent families

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
notable patents all others Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Pharmaceutical Dosage Forms Comprising 6'-Fluoro-(N-Methyl- or N,N-Dimethyl-)-4-Phenyl-4',9'-Dihydro-3'H-Spiro[Cyclohexane-1,1'-Pyrano[3,4,b]Indol]-4-Amine US 9,289,416
The most cited patent in this portfolio, cited by 45 later US patents, top 10% of utility patents granted in 2016 in our data. Protection runs to 2031.
Ends Aug 2031 · High confidence
Also notable
Process for the Preparation of 5-Fluorotryptophol US 10,323,040
Granted 2019. Computed term ends 2035.
Ends Apr 2035 · High confidence
Also notable
Titration of Cebranopadol US 11,229,625
Granted 2022. Computed term ends 2037.
Ends Feb 2037 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Dec 18, 2026
    The maintenance fee for Process for the Preparation of 5-Fluorotryptophol (US 10,323,040) comes due Dec 18, 2026. Unpaid by Jun 21, 2027, it lapses early.
  • 1 fee due Sep 22, 2027
    The maintenance fee for Pharmaceutical Dosage Forms Comprising 6'-Fluoro-(N-Methyl- or N,N-Dimethyl-)-4-Phenyl-4',9'-Dihydro-3'H-Spiro[Cyclohexane-1,1'-Pyrano[3,4,b]Indol]-4-Amine (US 9,289,416) comes due Sep 22, 2027. Unpaid by Mar 22, 2028, it lapses early.
  • 3 fees due Oct 12 to 26, 2027 · next Oct 12

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatusExpiresConfidence
US 9,289,416Pharmaceutical Dosage Forms Comprising 6'-Fluoro-(N-Methyl- or N,N-Dimethyl-)-4-Phenyl-4',9'-Dihydro-3'H-Spiro[Cyclohexane-1,1'-Pyrano[3,4,b]Indol]-4-Amine
In force
 · High confidence
In forceHigh confidence
US 10,912,763Pharmaceutical Dosage Forms Comprising 6'-Fluoro-(N-Methyl- or N,N-Dimethyl-)-4-Phenyl-4',9'-Dihydro-3'H-Spiro[Cyclohexane-1,1'-Pyrano[3,4,b]Indol]-4-Amine
In force
 · High confidence
In forceHigh confidence
US 8,658,827Method for Synthesizing Substituted Aminocyclohexanone Compounds
In force
 · High confidence
In forceHigh confidence
US 8,614,245Crystalline (1r, 4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine
In force
 · High confidence
In forceHigh confidence
US 8,618,156Crystalline (1R,4R)-6'-Fluoro-N,N-DIMETHYL-4-Phenyl-4',9'-Dihydro-3'H-SPIRO[CYCLOHEXANE-1,1'-Pyrano[3,4,B]INDOL]-4-Amine
In force
 · High confidence
In forceHigh confidence
US 8,912,343Solid Forms of (1 R,4R)-6' -Fluoro-(n, N-DIMETHYL)-4-Phenyl-4' ,9'-Dihydro-3'H-SPIRO[ CYCLOHEXANE-1,1 '-PYRANO-[3,4,B]INDOL]-4-Amine and Sulfuric Acid
In force
 · High confidence
In forceHigh confidence
US 8,779,160Process for the Preparation of (1R,4R)-6'-Fluoro-(N,N-DIMETHYL- and N-METHYL)-4-Phenyl-4',9'-Dihydro-3'H-SPIRO[CYCLOHEXANE-1,1'-Pyrano-[3,4,B]INDOL]-4-Amine
In force
 · High confidence
In forceHigh confidence
US 8,895,604Solid forms of (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3' H-spiro-[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine hydrochloride
In force
 · High confidence
In forceHigh confidence
US 8,912,226Pharmaceutical Composition Comprising (1R,4R)-6'-Fluoro-N,N-DIMETHYL-4-Phenyl-4',9'-Dihydro-3'H-SPIRO[CYCLOHEXANE-1,1'-Pyrano[3,4,B]INDOL]-4-Amine and a Nsar
In force
 · High confidence
In forceHigh confidence
US 9,320,725Pharmaceutical Composition Comprising (1R,4R)-6'-Fluoro-N,N-DIMETHYL-4-Phenyl-4'9'-Dihydro-3'H-SPIRO[CYCLOHEXANE-1,1'-Pyrano[3,4,B]INDOL]-4-Amine and a Gabapentinoid
In force
 · High confidence
In forceHigh confidence
10 of 19 patents shown.
Pro members see all 19.
Pro members: see all 19 patents
Also on record, not counted in the 19: 1 patent in force now held by others · 5 patents ended · 3 applications pending. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited